$5.10
-0.07[-1.35%]
At close: Apr 22
$5.10
0[0.00%]
PreMarket: 7:01AM EDT
Lyra Therapeutics
(NASDAQ:LYRA)Lyra Therapeutics Stock (NASDAQ:LYRA), Analyst Ratings, Price Targets, Predictions
Lyra Therapeutics Inc has a consensus price target of $14.6, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from B of A Securities, HC Wainwright & Co., and BTIG on March 25, 2024, March 22, 2024, and October 6, 2023. With an average price target of $12.67 between B of A Securities, HC Wainwright & Co., and BTIG, there's an implied 148.37% upside for Lyra Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
B of A Securities
HC Wainwright & Co.
BTIG
BTIG
Cantor Fitzgerald
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Lyra Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 03/25/2024 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 115.69% | B of A Securities | Jason Gerberry | $12 → $11 | Maintains | Buy | Get Alert |
| 03/22/2024 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 135.29% | HC Wainwright & Co. | Matthew Caufield | → $12 | Reiterates | Buy → Buy | Get Alert |
| 10/06/2023 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 194.12% | BTIG | Justin Zelin | → $15 | Assumes | → Buy | Get Alert |
| 10/02/2023 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 135.29% | HC Wainwright & Co. | Matthew Caufield | → $12 | Reiterates | Buy → Buy | Get Alert |
| 09/12/2023 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 194.12% | B of A Securities | Jason Gerberry | $13 → $15 | Maintains | Buy | Get Alert |
| 08/31/2023 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 135.29% | HC Wainwright & Co. | Matthew Caufield | → $12 | Initiates | → Buy | Get Alert |
| 02/07/2023 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 292.16% | BTIG | Robert Hazlett | $24 → $20 | Maintains | Buy | Get Alert |
| 05/24/2022 | LYRA | Buy Now | Lyra Therapeutics | $5.10 | 194.12% | Cantor Fitzgerald | Louise Chen | → $15 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Lyra Therapeutics (LYRA)?
The latest price target for Lyra Therapeutics (NASDAQ: LYRA) was reported by B of A Securities on March 25, 2024. The analyst firm set a price target for $11.00 expecting LYRA to rise to within 12 months (a possible 115.69% upside). 6 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lyra Therapeutics (LYRA)?
The latest analyst rating for Lyra Therapeutics (NASDAQ: LYRA) was provided by B of A Securities, and Lyra Therapeutics maintained their buy rating.
When was the last upgrade for Lyra Therapeutics (LYRA)?
There is no last upgrade for Lyra Therapeutics.
When was the last downgrade for Lyra Therapeutics (LYRA)?
There is no last downgrade for Lyra Therapeutics.
When is the next analyst rating going to be posted or updated for Lyra Therapeutics (LYRA)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lyra Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lyra Therapeutics was filed on March 25, 2024 so you should expect the next rating to be made available sometime around March 25, 2025.
Is the Analyst Rating Lyra Therapeutics (LYRA) correct?
While ratings are subjective and will change, the latest Lyra Therapeutics (LYRA) rating was a maintained with a price target of $12.00 to $11.00. The current price Lyra Therapeutics (LYRA) is trading at is $5.10, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.